Washingtonmyrick3150

Scores for most patient feedback questions were significantly positively correlated with weekly PRO completion rates in both univariate and multivariable analyses. Among 57 nurses, most reported that PRO information was helpful for clinical documentation (79%), increased efficiency of patient discussions (84%), and was useful for patient care (75%). Among 39 oncologists, most found PRO information useful (91%), with 65% using PROs to guide patient discussions sometimes or often and 65% using PROs to make treatment decisions sometimes or often.

These findings support the clinical utility and value of implementing digital systems for monitoring PROs, including the PRO-CTCAE, in routine cancer care.

These findings support the clinical utility and value of implementing digital systems for monitoring PROs, including the PRO-CTCAE, in routine cancer care.A key aim of early clinical development for new cancer treatments is to detect the potential for efficacy early and to identify a safe therapeutic dose to take forward to phase II. Because of this need, researchers have sought to build mathematical models linking initial radiologic tumor response, often assessed after 6 to 8 weeks of treatment, with overall survival. WAY-100635 ic50 However, there has been mixed success of this approach in the literature. We argue that evolutionary selection pressure should be considered to interpret these early efficacy signals and so optimize cancer therapy.

Some 20 y ago, scientific and regulatory communities identified the potential of omics sciences (genomics, transcriptomics, proteomics, metabolomics) to improve chemical risk assessment through development of toxicogenomics. Recognizing that regulators adopt new scientific methods cautiously given accountability to diverse stakeholders, the scope and pace of adoption of toxicogenomics tools and data have nonetheless not met the ambitious, early expectations of omics proponents.

Our objective was, therefore, to inventory, investigate, and derive insights into drivers of and obstacles to adoption of toxicogenomics in chemical risk assessment. By invoking established social science frameworks conceptualizing innovation adoption, we also aimed to develop recommendations for proponents of toxicogenomics and other new approach methodologies (NAMs).

We report findings from an analysis of 56 scientific and regulatory publications from 1998 through 2017 that address the adoption of toxicogenomics for chemical ri may be undermining efforts to promote toxicogenomics. https//doi.org/10.1289/EHP6500.

We identify the most salient drivers and obstacles. From 1998 through 2017, adoption of toxicogenomics was understood to be helped by drivers such as those we labeled Superior scientific understanding, New applications, and Reduced cost & increased efficiency but hindered by obstacles such as those we labeled Insufficient validation, Complexity of interpretation, and Lack of standardization. Leveraging social science frameworks, we find that arguments for adoption that draw on the most salient drivers, which emphasize superior and novel functionality of omics as rationales, overlook potential adopters' key concerns simplicity of use and compatibility with existing practices. We also identify two perspectives-innovation-centric and adopter-centric-on omics adoption and explain how overreliance on the former may be undermining efforts to promote toxicogenomics. https//doi.org/10.1289/EHP6500.

The purpose of this study was to review the literature to examine the usage and magnitude of effective dose conversion factors (DC

) for dental cone beam CT (CBCT) scanners.

A PubMed literature search for publications relating to radiation dosimetry in dental radiography was performed. Papers were included if they reported DC

, or reported ICRP 103 effective dose and dose-area product. 71 papers relating to dental CBCT dosimetry were found, of which eight reported effective dose conversion factors or provided enough information to calculate dose conversion factors. Scanner model, effective dose, dose-area product, tube voltage, field of view size and DC

were extracted from the papers for analysis.

DC

values ranged from 0.035 to 0.31 µSv/mGy-cm

with a mean of 0.129 µSv/mGy-cm

(SD = 0.056). When categorized into small (<100 cm

), medium (100-225 cm

) and large (>225 cm

) fields of view (FOV), linear fits to the effective dose and dose-area product yielded slopes of 0.129, 0.111 and 0.074 µSv/mGy-cm

for small, medium and large FOVs respectively.

The range of reported DC

values and spread with respect to field of view category suggests that DC

values that depend on FOV would provide more accurate effective dose estimates. Tube voltage was found to be a smaller factor in determining DC

. Reasonable values for DC

taking into account FOV size were obtained. There is considerable room for more work to be done to examine the behaviour of DC

with changes to patient age and dental CBCT imaging parameters.

The range of reported DCE values and spread with respect to field of view category suggests that DCE values that depend on FOV would provide more accurate effective dose estimates. Tube voltage was found to be a smaller factor in determining DCE. Reasonable values for DCE taking into account FOV size were obtained. There is considerable room for more work to be done to examine the behaviour of DCE with changes to patient age and dental CBCT imaging parameters.Objective This study aims to explore the role and regulatory mechanism of hsa-miR-147b in lung squamous cell carcinoma (LUSC) through The Cancer Genome Atlas (TCGA) database. Methods The expression and clinical value of miR-147b in LUSC were analyzed in the TCGA database. The target genes of miR-147b were screened via miRWalk 2.0 and verified in TCGA database. Gene ontology (GO) annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) were performed to analyzed the differential target genes of miR-147b. Kaplan-Meier survival analysis and Cox regression were used to screen the prognosis-related target genes. Results The expression of miR-147b in LUSC tissues increased, and was associated with poor prognosis, gender, and stage of LUSC patients. The area under the curve (AUC) of miR-147b was 0.8478 by the receiver-operating characteristic curve. There were 428 differentially expressed genes of miR-147b that played a critical role in drug transport, DNA binding, calcium signaling pathway, and Ras signaling pathway through GO and KEGG.